HRT reduces cardiovascular endpoints in ten-year trial

Brown, Simon
December 2012
Menopause International;Dec2012, Vol. 18 Issue 4, p127
Academic Journal
The article informs that according to a randomized clinical trial which was conducted in Denmark and which involved 1,000 postmenopausal women, the use of hormone replacement therapy resulted in fewer cardiovascular events such as heart failure, death and myocardial infarction. It informs that these women were treated with triphasic estradiol and norethisterone acetate for 11 years.


Related Articles

  • Digesting the alphabet soup of major studies.  // Patient Care;7/15/1994, Vol. 28 Issue 12, p136 

    Highlights the results of clinical trials, conducted in connection with myocardial infarction research. Includes long-term angiotensin-converting-enzyme inhibition; Atherectomy; Effectiveness of streptokinase; Prehospital administration of thrombolytics.

  • Applying results of randomised trials to clinical practice: impact of losses before randomisation. Charlson, Mary E.; Horwitz, Ralph I. // British Medical Journal (Clinical Research Edition);11/10/1984, Vol. 289 Issue 6454, p1281 

    Examines the magnitude and source of prerandomization losses in clinical trials. Criteria for entering patients; Assessment of generalisability; Effectiveness of timolol in myocardial infarction.

  • Transdermal hormone therapy: less haemostatic activation?  // Reactions Weekly;5/26/2007, Issue 1153, p4 

    The article discusses research being done on hemostatic activation in post-menopausal women taking low-dose hormone therapy. It references a study by J. F. Brosnan and colleagues published in the April 2007 issue of "Thrombosis and Haemostasis." The study enrolled 344 healthy post-menopausal...

  • COMMENTARY: Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction. Borzak, Steven // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29 

    The article comments on the study related to the use of the drug fondaparinux to treat patients with acute ST-segment elevation myocardial infarction (STEMI). In the study fondaparinux was found useful in reducing death. These trials support the use of anticoagulant therapy in patients with...

  • Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial. Lexis, Chris; Horst, Iwan; Lipsic, Erik; Harst, Pim; Horst-Schrivers, Anouk; Wolffenbuttel, Bruce; Boer, Rudolf; Rossum, Albert; Veldhuisen, Dirk; Smet, Bart // Cardiovascular Drugs & Therapy;Oct2012, Vol. 26 Issue 5, p417 

    Background: Left ventricular dysfunction and the development of heart failure is a frequent and serious complication of myocardial infarction. Recent animal experimental studies suggested that metformin treatment reduces myocardial injury and preserves cardiac function in non-diabetic rats after...

  • Cardiology today Trial Scorecards.  // Cardiology Today;Nov2013, Vol. 16 Issue 11, p9 

    The article summarizes cardiological studies as of November 2013 on topics including the effect of metoprolol on patients undergoing acute myocardial infarctions, the effectiveness of alogliptin on patients with diabetes, and the effect of nerve stimulation on patients with sleep apnea.

  • Thrombolytics in elderly patients: A triumph of hope over experience? Thiemann, David R.; Schulman, Steven P. // CMAJ: Canadian Medical Association Journal;5/01/2001, Vol. 164 Issue 9, p1301 

    Discusses the study of the use of thrombolytic therapy for elderly patients with acute myocardial infarction (AMI). Decreased use of thrombolytic therapy with age; Question whether the low use harms elderly patients with AMI; Indication from other trials that the benefit of thrombolysis...

  • Statin use to reduce the incidence of PCI-associated periprocedural MI. Sim, Michael // Cardiology Today;Feb2011, Vol. 14 Issue 2, p15 

    The article discusses the findings of the ARMYDA and the Novel Approaches for Preventing or Limiting Events II (NAPLES II) trials which both demonstrated the beneficial effects of statins in reducing the incidence of periprocedual myocardial infarction (MI).

  • Stable rhythms.  // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p122 

    Reports on the results of an international clinical study of Lovenox (enoxaparin) as a treatment for unstable angina or non-Q-wave heart attacks which appeared in the August 13, 1997 issue of the `New England Journal of Medicine.' Reduced risk of death, myocardial infarction and recurrent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics